Beijing Tide Pharmaceutical Becomes Biggest Shareholder Of Japanese LTT Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
According to a recent disclosure filed by LTT Bio-Pharma, a Japanese biotech startup focusing on drug delivery system discovery, Beijing Tide Pharmaceutical acquired 2,320 company shares previously owned by now-bankrupt Asklepios and became the largest shareholder with 25,320 shares. The shares account for 19.2 percent of LTT Bio-Pharma's outstanding shares. (Click here for more - Japanese language